Advertisement

Drug Delivery and Translational Research

, Volume 9, Issue 5, pp 980–996 | Cite as

Development of anti-angiogenic erlotinib liposomal formulation for pulmonary hypertension: a QbD approach

  • Sagar Dhoble
  • Vandana PatravaleEmail author
Original Article

Abstract

Pulmonary arterial hypertension (PAH) is the increase in mean pulmonary arterial pressure (> 25 mmHg). The development of the non-reversible plexiform lesions on the arterial walls of the pulmonary arteries has evolved as the reason to increase the pressure. The current treatments are directed towards the vasodilation of the pulmonary arteries via the endothelin, prostacyclin, and NO pathways which provides symptomatic relief. Deeper understanding of the disease leads to the various pathophysiological targets that play an important role in the development of PAH. Out of these, the angiogenetic mechanism of the pulmonary arterial smooth muscle cells has been proved to play an important role in PAH. Targeted therapies by anti-proliferative drugs may lead to the efficient treatment strategies to the root cause of PAH. Erlotinib, a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR), has shown promising results in clinical trials of PAH. The objective of the work has been the development of liposomal formulation of anti-proliferative drug, erlotinib HCl, via Quality by Design (QbD) approach. The liposomal formulation was developed using thin-film hydration technique and characterised for various physicochemical parameters, like particle size, % entrapment efficiency, DSC, FTIR, pXRD, and TEM. In the drug release study, the formulation showed sustained release of erlotinib over 24 h in simulated lung fluid pH 7.4. This developed formulation was evaluated in zebrafish tail fin regeneration assay for its anti-angiogenetic activity. The liposomal formulation inhibited the tail fin regeneration for 14 days indicating anti-angiogenetic activity.

Keywords

Pulmonary arterial hypertension Angiogenesis Quality by Design Liposomes Zebrafish 

Notes

Ethical approval and animal care and use

All institutional and national guidelines for care and use of laboratory animals were followed.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

13346_2019_641_MOESM1_ESM.docx (18 kb)
ESM 1 (DOCX 17 kb)

References

  1. 1.
    Sutendra G, Michelakis ED. The metabolic basis of pulmonary arterial hypertension. Cell Metab. 2014;19(4):558–73.CrossRefPubMedGoogle Scholar
  2. 2.
    George MG, Schieb LJ, Ayala C, Talwalkar A, Levant S. Pulmonary hypertension surveillance United States, 2001 to 2010. Chest. 2014;146(2):476–807.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Duarte JD, Hanson RL, Machado RF. Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. Futur Cardiol. 2013;9(3):335–49.CrossRefGoogle Scholar
  4. 4.
    Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51(16):1527–38.CrossRefPubMedGoogle Scholar
  5. 5.
    McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976–97.CrossRefPubMedGoogle Scholar
  6. 6.
    McLaughlin VVMD, McGoon MDMD. Pulmonary arterial hypertension. Circ. 2006;114:1417–31.CrossRefGoogle Scholar
  7. 7.
    Smythe W, Mcilleron H, Merle C, Horton J, Smith P, Simonsson, USH. A semi-mechanistic pharmacokinetic auto-induction model for the characterisation of rifampicin pharmacokinetics in African pulmonary tuberculosis infected adults. Poster Abstracts page 2010, 39.Google Scholar
  8. 8.
    Frumkin LR. The pharmacological treatment of pulmonary arterial hypertension. Pharmacol Rev. 2012;64(3):583–620.CrossRefPubMedGoogle Scholar
  9. 9.
    Sakao S, Tatsumi K, Voelkel NF. Reversible or irreversible remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2010;43(6):629–34.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Vaidya B, Gupta V. Novel therapeutic approaches for pulmonary arterial hypertension: unique molecular targets to site-specific drug delivery. J Control Release. 2015;211:118–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Galie N, Ghofrani A-H. New horizons in pulmonary arterial hypertension therapies. Eur Respir Rev. 2013;22(130):503–14.CrossRefPubMedGoogle Scholar
  12. 12.
    Chakraborty C, Hsu CH, Wen ZH, Lin CS, Agoramoorthy G. Zebrafish: a complete animal model for in vivo drug discovery and development. Curr Drug Metab. 2009;10(2):116–24.CrossRefPubMedGoogle Scholar
  13. 13.
    Rubinstein AL. Zebrafish: from disease modeling to drug discovery. Curr Opin Drug Di De. 2003;6:218–23.Google Scholar
  14. 14.
    Chávez MN, Aedo G, Fierro FA, Allende ML, Egaña JT. Zebrafish as an emerging model organism to study angiogenesis in development and regeneration. Front Physiol. 2016;7(MAR):1–15.Google Scholar
  15. 15.
    Xu H, He C, Liu Y, Jiang J, Ma T. Novel therapeutic modalities and drug delivery—erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations. Artif Cell Nanomed B. 2018;46(8):1902–7.Google Scholar
  16. 16.
    Nimmano N, Somavarapu S, Taylor KM. Aerosol characterisation of nebulised liposomes co-loaded with erlotinib and genistein using an abbreviated cascade impactor method. Int J Pharm. 2018;542(1–2):8–17.CrossRefPubMedGoogle Scholar
  17. 17.
    Pitsiou G, Zarogoulidis P, Petridis D, Kioumis I, Lampaki S, Organtzis J, et al. Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment. Drug Des Dev Ther. 2014;8:1753–63.Google Scholar
  18. 18.
    Xu X, Khan MA, Burgess DJ. A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. Int J Pharm. 2012;423(2):543–53.CrossRefPubMedGoogle Scholar
  19. 19.
    Sylvester B, Porfire A, Muntean DM, Vlase L, Lupuţ L, Licarete E, et al. Optimization of prednisolone-loaded long-circulating liposomes via application of quality by design (QbD) approach. J Lipos Res. 2018;28(1):49–61.CrossRefGoogle Scholar
  20. 20.
    ICH. Pharmaceutical development Q8. ICH Harmon Tripart Guidel. 2009;8(August):1–28.Google Scholar
  21. 21.
    Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588–99.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    ICH Expert Working Group. Quality risk management Q9. ICH Harmon Tripart Guidel. 2005;(November):1–23.Google Scholar
  23. 23.
    Roy B, Guha P, Bhattarai R, Nahak P, Karmakar G, Chettri P, et al. Influence of lipid composition, pH, and temperature on physicochemical properties of liposomes with curcumin as model drug. J Oleo Sci. 2016;65(5):399–411.CrossRefPubMedGoogle Scholar
  24. 24.
    Mahmoud M, Labiba N, Khalil EK, Khalafallah N. Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles. Acta Pol Pharm Drug Res. 2005;62(5):369–79.Google Scholar
  25. 25.
    Kulkarni SB, Betageri GV, Singh M. Factors affecting microencapsulation of drugs in liposomes. J Microencapsul. 1995;12(3):229–46.CrossRefPubMedGoogle Scholar
  26. 26.
    Makrilia N, Lappa T, Xyla V, Nikolaidis I, Syrigos K. The role of angiogenesis in solid tumours: an overview. Eur J Intern Med. 2009;20(7):663–71.CrossRefPubMedGoogle Scholar
  27. 27.
    Poss KD, Keating MT, Nechiporuk A. Tales of regeneration in zebrafish. Dev Dynam. 2003;226(2):202–10.CrossRefGoogle Scholar
  28. 28.
    Schuermann A, Helker CSM, Herzog W. Angiogenesis in zebrafish. Semin Cell Dev Biol. 2014;31:106–14.CrossRefPubMedGoogle Scholar
  29. 29.
    Eyries M, Siegfried G, Ciumas M, Montagne K, Agrapart M, Lebrin F, et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res. 2008;103(4):432–40.CrossRefPubMedGoogle Scholar
  30. 30.
    Rathinasamy VS, Paneerselvan N, Jagadeeshan S, Malathi R. Hypoxia induced angiogenesis and upregulation of VEGF: an in vivo study using zebrafish model. Int J Sci Eng Res. 2015;6(6):831–9.Google Scholar

Copyright information

© Controlled Release Society 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences and TechnologyInstitute of Chemical TechnologyMatungaIndia

Personalised recommendations